Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer

• Published in: Biochemical and biophysical research communications Vol. 469; no. 15; pp. 679 - 685
• Main Authors: Gao, Xuemei, Xinchao Wu, Xiao Zhang, Wenjuan Hua, Yajing Zhang, Yusufu Maimaiti, Zairong Gao, Yongxue Zhang
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 2016
• Subjects: BRD4; C-MYC; cell cycle checkpoints; drug therapy; endocrine system; genes; histones; humans; interphase; iodine; JQ1; neoplasm cells; NIS; patients; promoter regions; Thyroid cancer; thyroid neoplasms
• ISSN: 0006-291X; 1090-2104

Thyroid cancer is a common malignancy of the endocrine system. Although radioiodine 131I treatment on differentiated thyroid cancer is widely used, many patients still fail to benefit from 131I therapy. Therefore, exploration of novel targeted therapies to suppress tumor growth and improve radioiodine uptake remains necessary. Bromodomain-containing protein 4 (BRD4) is an important member of the bromodomain and extra terminal domain family that influences transcription of downstream genes by binding to acetylated histones. In the present study, we found that BRD4 was up-regulated in thyroid cancer tissues and cell lines. Inhibition of BRD4 in thyroid cancer cells by JQ1 resulted in cell cycle arrest at G0/G1 phase and enhanced 131I uptake in vitro and suppressed tumor growth in vivo. Moreover, JQ1 treatment suppressed C-MYC but enhanced NIS expression. We further demonstrated that BRD4 was enriched in the promoter region of C-MYC, which could be markedly blocked by JQ1 treatment. In conclusion, our findings revealed that the aberrant expression of BRD4 in thyroid cancer is possibly involved in tumor progression, and JQ1 is potentially an effective chemotherapeutic agent against human thyroid cancer.